While the results for heart and back pain are promising and the trials are well advanced, I'm surprised more effort on Crohn's disease hasn't been prioritised. The results we saw, albeit with a small cohort, looked fantastic. Best of all the timescales for effect seem extraordinarily short ~30 days and the clear evidence of improvement is easy to obtain and not really something that can be debated. Add to this the large number of people that have acute cases and we should be able to produce a trial with a very fast turn around for results for what would be a very lucrative market that is crying out for a solution.
While the results for heart and back pain are promising and the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.000(0.00%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 70 | 1 |
View Market Depth
| Last trade - 09.42am 08/05/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable